Kymera Therapeutics kymeratx.com


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

Kymera Therapeutics (NASDAQ: KYMR) is a biotechnology company that develops an approach to treating previously untreatable diseases. Kymera aims to accelerate drug discovery with an ability to target and degrade proteins and advance treatment options for patients.

Kymera Therapeutics (NASDAQ: KYMR) is a biotechnology company that develops an approach to treating previously untreatable diseases. Kymera aims to accelerate drug discovery with an ability to target and degrade proteins and advance treatment options...Show all

Company (IPO / Went public)

Phone: 857-285-5314

Fax:

300 Technology Square
2nd Floor
Cambridge, 02139
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Kymera Therapeutics $197M Aug 21, 2020

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Kymera Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 20 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Irak degraders and uses thereof Dec 21, 2018 Dec 29, 2020 Patent
Tricyclic crbn ligands and uses thereof Jul 03, 2019 Application
Crbn ligands and uses thereof Jan 14, 2019 Application
Protein degraders and uses thereof Jan 14, 2019 Application
Crbn ligands and uses thereof Sep 21, 2018 Application